Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University | OTHER |
| Shanghai Zhongshan Hospital | OTHER |
| Henan Provincial People's Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging technology prediction model of adverse events, screening the best non-invasive imaging prediction indicators.
This study will enrolled 1000 HT patients, and the cardiac allograft vasculopathy will be evaluated by multimodal imaging technology. The aim is to (1) establish a system of multimodal imaging technology; (2) jointly apply multimodal imaging technology to diagnose of cardiac allograft vasculopathy of heart transplantation; (3) construct a multimodal imaging technology prediction model of adverse events, screening the best non-invasive imaging prediction indicators.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CAV 0(Not significant) | No detectable angiographic lesion | ||
| CAV 1 (Mild) | Angiographic left main (LM) <50%, or primary vessel with maximum lesion of <70%, or any branch stenosis <70% (including diffuse narrowing) without allograft dysfunction | ||
| CAV 2 (Moderate) | Angiographic LM <50%; a single primary vessel≥70%, or isolated branch stenosis ≥70% in branches | ||
| CAV 3 (Severe) | Angiographic LM≥50%, or two or more primary vessels ≥70% stenosis, or isolated branch stenosis≥70%in all 3 systems; or CAV1 or CAV2 with allograft dysfunction (defined as LVEF≤45% usually in the presence of regional wall motion abnormalities) or evidence of significant restrictive physiology |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| All cause death | All cause death after HT was obtained via telephone interview with family members; contact with his/her physicians; or hospital records | up to 10 year |
| Measure | Description | Time Frame |
|---|---|---|
| Major adverse cardiac events | Major adverse cardiac events after the inclusion of the study was obtained via telephone interview with family members; contact with his/her physicians; or hospital records | 5 year and 10 year |
Not provided
Inclusion Criteria:
• Heart transplantation after January 1st, 2015.
Exclusion Criteria:
•Age < 18 years at the time of transplantation; Died within 48 h; Heart-lung transplantation; Heart/kidney transplantation; Re-transplanted within 7 days after transplantation.
Not provided
Not provided
All adult HT recipients were consecutive prospectively enrolled who underwent transthoracic echocardiography for surveillance at their routine follow-up
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Li Zhang, PhD | Contact | 18907131488 | zli429@hust.edu.cn | |
| Shuangshuang Zhu, MD | Contact | 15971428009 | 18846032209@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Li Zhang, PhD | Department of Ultrasound, Union Hospital, Wuhan, China | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Wuhan Asia Heart Hospital |
| OTHER |
| Guangdong Provincial People's Hospital | OTHER |
Not provided
Not provided
Not provided